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Summary
Background: The TOR (target of rapamycin) ser/thr pro-
tein kinase is the central component of a eukaryotic sig-
naling pathway that regulates growth and is the direct
target of the clinically useful drug rapamycin. Recent ef-
forts have identified at least two multiprotein complexes
that contain TOR, but little is known in higher eukaryotes
about the genes downstream of TOR that control growth.
Results: By combining the use of a small molecule in-
hibitor (rapamycin), transcriptional profiling, and RNA in-
terference in Drosophila tissue culture cells, we identi-
fied genes whose expression responds to Drosophila
TOR (dTOR) inhibition and that regulate cell size. Several
of the dTOR-regulated genes that function in cell size
control have additional roles in cell division. Most of
these genes are conserved in mammals and several
are linked to human disease. This set of genes is highly
enriched for regulators of ribosome biogenesis, which
emphasizes the importance of TOR-dependent tran-
scription in building the protein synthesis machinery in
higher eukaryotes. In addition, we identify two dTOR-
regulated genes, CG3071 and CG6677, whose human
orthologs, SAW and ASH2L, are also under TOR-depen-
dent transcriptional control and encode proteins with
conserved functional roles in growth.
Conclusions: We conclude that combining RNA inter-
ference with genomic analysis approaches, such as tran-
scriptional profiling, is an effective way to identify genes
functioning in a particular biological process. Moreover,
this strategy, if applied in model systems with simpler
genomes, can identify genes with conserved functions
in mammals.
Introduction
Cell growth is the process by which cells accumulate
mass. mTOR, a large ser/thr protein kinase and the direct
target of the clinically important drug rapamycin, is a
critical and conserved regulator of growth [1]. Studies
in yeast, Drosophila, and mammalian cultured cells
*Correspondence: sabatini@wi.mit.eduindicate that mTOR functions in two distinct complexes
called mTOR complex 1 and 2 (mTORC1 and mTORC2),
respectively [2–8]. Both complexes contain mTOR and
a small WD-repeat protein GbetaL (GbL), but their sub-
strate specificities are determined by interactions be-
tween mTOR and two unique accessory proteins, Raptor
and Rictor. mTORC1, which is sensitive to rapamycin,
contains Raptor and controls cell growth. mTORC2,
which is bound by Rictor, is not a direct target of rapamy-
cin and is predicted to have a role in cell survival and cell
proliferation.
mTORC1 lies downstream of the TSC1 and TSC2
genes, which are mutated in TSC (Tuberous Sclerosis
Complex) and the related disease LAM (Lymphangio-
leiomyomatosis) [9]. The TSC1 and TSC2 proteins form
a two-component GTPase activating protein (GAP)
complex that inhibits mTORC1 growth signaling through
a small GTPase called Rheb in response to nutrient sta-
tus, energy availability, stress, and growth factors [1].
One well-described downstream target of mTORC1 is
the S6 kinase 1 (S6K1) [1]. mTORC1 activates S6K1 by
directly phosphorylating it in a C-terminal hydrophobic
motif. mTOR knockout models in Drosophila and mice
are early lethal, but in contrast, knockout models of
S6K1 are viable and reduced in size, suggesting that
S6K1 contributes to the growth response but other out-
puts of mTORC1 are important [10–16]. mTORC1 also
phosphorylates and inhibits the eIF-4E binding protein
1 (4E-BP1). eIF-4E, which is inhibited through direct
binding of 4E-BP1, promotes cap-dependent transla-
tion. In Drosophila and mice, 4E-BP1 is dispensable for
viability and in Drosophila 4E-BP is required under
stressful conditions to halt metabolism and promote
survival [17, 18]. An important inhibitory role for mTORC1
in autophagy, a cellular process of self-digestion, is also
emerging [19].
The rate of cell growth correlates with ribosome num-
ber in addition to the efficiency of translation initiation. In
yeast, it is the combined rate of rRNA and ribosomal pro-
tein transcription that determines the rate of ribosome
biogenesis [20]. It is also well established in yeast that
TOR-dependent control of protein synthesis involves
transcriptional regulation of ribosome biogenesis genes
[21, 22]. Yeast TOR modulates ribosome biogenesis
through controlling rRNA and ribosomal protein tran-
scription [21–23]. The transcription of a large number
of genes called the Ribi regulon, many of which encode
ribosome assembly factors [24–28], is also influenced
by TOR signaling in yeast [29]. mTOR-dependent tran-
scriptional regulation of rRNA in mammalian cells is ra-
pamcyin sensitive [30–33], but whether mTOR signaling
coordinates rRNA transcription with transcription of ri-
bosomal proteins and ribosome assembly factors is still
unclear.
Recent work revealed that the mTORC1 growth path-
way is hyperactive in many cancers, propelling rapamy-
cin into clinical trials as a treatment for certain cancers,
TSC, and LAM [1, 9]. One model suggests that loss of
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959Figure 1. Growth Is Inhibited by Rapamycin in Drosophila S2 Cells
(A)Drosophila S2 cells were treated with rapamycin at the indicated concentrations. A time course experiment indicates that S2 cells decrease in
size and arrest division within 24 hr of rapamycin treatment. By 72 hr post rapamycin addition, the cell size defect partially recovers but cells
remain arrested. The average value and standard deviation for three independent measurements are shown for each data point.
(B) Rapamycin treatment results in rapid and complete dephosphorylation of dS6K1 T398, which is equivalent to the mTOR-dependent T389
hydrophobic motif site in mammalian S6K1. Ethanol, the rapamycin solvent and vehicle control, reproducibly decreases dS6K1 phosphorylation
modestly at 60 min, consistent with reports that alcohol can impair phosphorylation of S6K1 [41, 42].PTEN function promotes Akt/PKB-dependent inhibition
of TSC2 and activation of mTORC1 [34–36], although the
physiological significance of this event has been ques-
tioned [37]. The prevailing view is that an activated
mTORC1 promotes protein synthesis through S6K1 and
4E-BP1 and gives tumors a growth advantage. Transcrip-
tional profiling in yeast and mammalian cells indicates
that mTORC1 additionally regulates a diverse array of
genes that could also impact tumor progression [21,
38–40]. mTORC1-responsive genes could be utilized
as biomarkers of mTOR activity as well as potential tar-
gets for antigrowth drugs.
Considering the significance of mTOR signaling in
cancer, we devised a strategy that combines gene-
expression profiling with RNAi-based loss-of-function
analysis to screen for genes regulated by TOR that func-
tion in growth control. To improve the probability of find-
ing growth genes, we first identified a set of genes
whose transcription is rapidly responsive to Drosophila
TORC1 (dTORC1) inhibition by acute rapamcyin treat-
ment of cultured cells. We next determined the func-
tional role of each dTOR-regulated gene in cell size con-
trol by RNAi. This approach identified several regulators
of cell growth, some of which also have roles in cell divi-
sion control. A significant proportion of the identified
genes function in multiple steps along the ribosome as-
sembly pathway, emphasizing the intimate link between
ribosome biogenesis and cell size regulation and sug-
gesting that in higher eukaryotes as in yeast, TOR has
a critical and complex role in controlling protein synthe-
sis on many different levels. Finally, we identified dTOR-
regulated growth genes that are also transcriptionally
regulated in mammalian cells by mTOR and that have
a conserved functional role in growth.Results
Identification of Genes Responsive to Acute
Rapamycin Treatment
To search for genes regulated by the TOR kinase, we
usedDrosophila cultured S2 cells as a model system be-
cause the TOR pathway is highly conserved in Drosoph-
ila, the Drosophila genome is less redundant than mam-
mals, and importantly for functional studies, these cells
are particularly amenable to RNAi. TOR bound to Raptor
is inhibited by rapamycin and controls growth, which
can be determined empirically by measuring cell size.
A time course experiment indicates that S2 cells de-
crease in size and arrest division within 24 hr of rapamy-
cin treatment at concentrations between 1 and 50 nM
(Figure 1A). By 72 hr post rapamycin addition, the cell
size defect partially recovers but cells remain arrested.
As expected, rapamycin treatment results in rapid and
complete dephosphorylation of dS6K1 T398, which is
equivalent to the mTOR-dependent T389 hydrophobic
motif site in mammal S6K1 (Figure 1B). Ethanol, the
rapamycin solvent and vehicle control, reproducibly
decreases dS6K1 phosphorylation modestly at 60 min,
consistent with reports that alcohol impairs phosphory-
lation of S6K1 [41, 42].
To identify genes regulated by dTOR, we generated
gene expression profiles of cultured S2 cells after 0,
30, 60, or 120 min of rapamycin treatment. 428 and 588
genes exhibited patterns of decreased or increased
expression, respectively, after the time course (see Fig-
ure S1 in the Supplemental Data available with this arti-
cle online). Of the genes significantly changing expres-
sion (p < 0.01), 35% and 42%, respectively, had gene
ontology (GO) annotations. Overrepresented among
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(A) Normalized cell size distributions of S2 cells knocked down for various positive and negative regulators of the dTOR growth pathway.
Target genes are indicated in the box and color coordinated with the appropriate lines on the graph. Cell size data is displayed below as
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control, Pol II transcription, programmed cell death, DNA
metabolism, and response to stress (Figure S2). Down-
regulated genes are overrepresented for genes func-
tioning in protein folding, ribosome biogenesis, electron
transport, protein targeting, oxidative phosphorylation,
mRNA processing, and protein transport.
We reasoned that the set of genes significantly re-
sponsive to rapamycin might have a high probability of
containing dTOR-regulated genes that function in growth
and/or division control. From the list of genes differen-
tially expressed after rapamycin treatment, we identified
a subset of 84 genes that significantly (p < 0.01) increase
or decrease expression 2-fold or more at each time point
(Figure S1). GO analysis of this filtered gene set indi-
cates that of the overrepresented genes decreasing in
expression, many function in Pol I transcription, rRNA
metabolism, ribosome biogenesis, and protein folding,
while transcription regulators are overrepresented among
genes increasing in expression (Figure S3).
dTOR-Regulated Genes Function in Growth Control
We hypothesized that many of the significant dTOR-reg-
ulated genes identified by expression profiling would
function in controlling cell growth. To explore this possi-
bility, we first established that RNAi-mediated silencing
of several dTOR pathway components in Drosophila S2
cells causes dramatic changes in cell growth as deter-
mined by measuring individual cell size (Figure 2A). For
instance, RNAi-mediated silencing of dTOR or dRaptor
results in a reduced mean cell diameter and a corre-
sponding decrease in dS6K phosphorylation (data not
shown), a phenotype reminiscent of rapamycin treat-
ment. Likewise, silencing dRheb decreases cell diameter
to a size comparable to dTOR- or dRaptor-silenced cells,
supporting the prediction that Rheb activates TORC1.
RNAi-mediated silencing of dS6K causes an intermedi-
ate reduction in cell size, which is consistent with genetic
studies. Similarly, silencing dAKT also reduced cell size.
Conversely, silencing the dTSC2 or dPTEN tumor sup-
pressors increases mean cell diameter, consistent with
their role as negative growth regulators. We converted
individual cell size distribution curves to one-dimen-
sional stacked images for visualizing many cell size
curves simultaneously (Figure 2A, bottom).
Since the cell size decrease resulting from knockdown
of dTOR, dRaptor, or dRheb more closely resembles ra-
pamycin treatment than does knockdown of dS6K (com-
pare Figures 1 and 2), we reasoned that other dTOR out-
puts might contribute to growth control. One possibility
is that the combined efforts of both dS6K and deIF-4E
(the negatively regulated target of the TOR substrate
4E-BP1) mediate TOR-dependent growth. Knockdown
of either dS6K1 or deIF-4E reduces mean cell diameter
to a similar degree (Figure 2B); however, silencing both
dS6K1 and deIF4-E together does not reduce mean cell
diameter to the same extent as rapamycin treatment
(Figure 2B). Although growth is inhibited here by two
different mechanisms (drug treatment versus RNAi),this comparison suggests that other dTOR outputs con-
tribute to growth.
We next used RNAi to systematically silence all of the
significant rapamycin-responsive genes that changed
2-fold and measured the resultant effects on cell size.
In total, 54 of the genes we screened (w65%) had a
cell size defect after RNAi, 49 of which were reproduc-
ible with a p value <0.05 (Figure 3 and Table S1). Ob-
served changes in cell size could reflect defects in cell
proliferation, so we additionally measured cell number.
Genes that reduce cell number to 65% or less of the con-
trol cell number when silenced were thus categorized
as having both cell-growth and cell-proliferation defects
(Figure 3B). Silencing of the remaining genes, in most
cases, had a significant effect on cell size while mini-
mally reducing cell number (Figure 2A). A detailed de-
scription of the genes identified can be found in Table
S2. This analysis identified both positive growth regula-
tors (genes that decrease cell size when silenced) and
negative growth regulators (genes that increase cell size
when silenced). Importantly, we identified genes that
when silenced decrease cell size to the same extent
as dTOR RNAi, as well as genes whose silencing led to
cell size increases comparable to silencing dTSC2 or
dPTEN silencing. There appears to be good correlation
between the gene expression response (down or up)
and effect on cell size (decrease or increase) such that
genes inhibited by rapamycin are generally positive
growth regulators, and at least two genes that increase
expression seem to be negative growth regulators. Most
of these Drosophila genes have human orthologs, some
of which are linked to diseases (see Table S2 and Dis-
cussion).
To confirm that the effects of rapamycin on gene ex-
pression reflect an inhibition of the dTOR growth path-
way, we compared the gene expression profiles from ra-
pamycin-treated cells with those from cells knocked
down for dRheb, dTOR, dRaptor, and dRictor. We did
not expect these comparisons to show dramatic over-
laps since the analysis compares the effects of an acute
drug treatment with those of chronic gene silencing.
However, k-means clustering (k = 3) of knockdown ex-
pression data revealed that silencing dRheb, dTOR,
and dRaptor generated expression profiles resembling
rapamcyin treatment (Figure 4A). The dRheb knock-
down profile was most similar with a Pearson correlation
of 0.40 (p value < 1e210) when compared to the 120 min
drug-treatment profile, followed by dTOR (0.29; p value <
1e25) and dRaptor (0.17; p value = 0.002). Consistent
with dRictor functioning in a rapamycin-insensitive
dTOR pathway, there was no correlation between the
dRictor and rapamycin profiles (20.06; p value = 0.9).
To further validate our approach and to test if the
genes we identified might be relevant to growth-related
diseases, we performed combination knockdown exper-
iments by silencing dTSC2 (a negative regulator of dTOR)
in combination with silencing several of the genes found
to positively regulate growth. Silencing dTSC2 results in
a large increase in mean cell diameter (Figures 2A anda one-dimensional stacked distribution of histograms ordered from smallest to largest mean cell diameter. Blue color indicates fewer cells in bin,
while yellow color indicates more cells.
(B) Normalized cell size distributions of cells knocked down for dS6K and/or deIF4E compared to rapamycin-treated cells. Note that in both
figures the x axis is nonlinear.
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Rapamycin-induced expression profiles and the corresponding cell size distributions after RNAi. The TOR-pathway components described in
Figure 2 are included as positive controls and their expression changes have been shaded gray. Cell size distributions are ordered from smallest
mean cell diameter (top) to largest (bottom). The corresponding cell number count after RNAi is indicated to the right. We arbitrarily decided that
a cell number count less thanw65% of the control qualified as a cell proliferation defect. The mean cell diameter and cell number of the control is
marked with a white and blue line, respectively. Knockdowns that induce cell size changes (A) and knockdowns that induce both cell size and cell
proliferation changes (B) are separated.
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(A) Gene expression signatures from rapamycin-treated cells are similar to signatures from cells knocked down for dRaptor, dTOR, and dRheb,
but not dRictor.
(B) Combination knockdown of candidate genes with dTSC2. We randomly selected 20 genes identified as positive growth regulators by our
screen and silenced them by RNAi alone or in combination with the negative growth regulator dTSC2. In all cases, silencing the candidate
gene in combination with dTSC2 reduced the cell size increase caused by silencing dTSC2. The dashed red line indicates the average cell
size for the GFP control cells.
(C) dTOR-regulated growth genes mediate ribosome assembly. Nearly 70% of the genes identified by our screen have a yeast ortholog that me-
diates ribosome assembly (yeast genes in red). The yeast/Drosophila gene pairs are listed next to the corresponding step in ribosome assembly
where they are predicted to function. Also listed are three yeast/Drosophila gene pairs identified that function in RNA polymerase I/III transcription.4B); however, the cell size increase was suppressed in
each case when we silenced a candidate positive growth
gene in combination with dTSC2 (Figure 4B). In most
cases, final average cell size in each combination knock-
down was close to the control average cell size rather
than the average cell size resulting from knockdown of
the candidate gene alone. This ‘‘equilibration’’ might rep-
resent the fact that gene knockdowns are not equivalent
to knockouts and residual protein expression persists.
Alternatively, it might reflect that downstream in the
dTOR growth pathway signaling branches and thesecandidate genes when silenced might only compromise
one output. Regardless, these data are consistent with
the identified genes functioning downstream of dTSC2
although it does not rule out that they could function in
a parallel pathway.
Rapamycin Decreases Expression of Ribosome
Assembly Genes that Control Growth
Since GO analysis of the filtered set of rapamycin-re-
sponsive genes revealed that ribosome biogenesis reg-
ulators are overrepresented among the known genes,
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(A) Real-time quantitative RT-PCR was used to measure changes in SAW and ASH2L mRNA levels in HEK293T cells after treatment with 20 nM
rapamycin for 0, 1, 2, or 3 hr.
(B) Real-time quantitative RT-PCR was performed as in (A) except that total RNA was prepared from HEK293T cells stably expressing lenti-viral
shRNAs that target GFP or mTOR for silencing.
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identified might also have roles in ribosome biogenesis.
We compared the sequence of each unidentified Dro-
sophila gene with its closest yeast ortholog by InPara-
noid V4.0 (http://inparanoid.cgb.ki.se/index.html). 70%
of all the genes in Figure 2 have a yeast ortholog with
a defined or predicted function (Table S3). Of the genes
decreasing expression in response to rapamycin, a strik-
ing 69% (33/48) have a budding yeast ortholog pre-
dicted or known to function in controlling ribosome
assembly. Review of current literature suggests that
these genes function at multiple steps of ribosome syn-
thesis including assembly of the 90S preribosomal par-
ticle (SSU processome) and assembly of both the 60S
and 40S subunit of the ribosome (Figure 4C) [43, 44].
Thus, in Drosophila S2 cells, acute rapamycin treatment
downregulates expression of genes that function in ribo-
some assembly pathways and have a role in maintaining
proper cell size and cell division control. Although rRNA
transcription is sensitive to rapamycin in mammalian
cells, a link between ribosome assembly factor tran-
scription and TOR signaling has not been described in
higher eukaryotes.
Consistent with the additional role for TOR signaling in
regulating rDNA transcription, three genes (CG18600,
CG3756, CG4033/Rpl135) identified in our functional as-
say as decreasing expression in response to rapamycin
and reducing size when silenced are predicted to en-
code components of the RNA pol I complex (Figure 4C).
The yeast ortholog of CG3756 is also part of the RNA pol
III complex. One gene (CG13096) is related to the human
Ribosomal L1 domain containing protein 1 and a second
gene (CG5033) is predicted to encode ribonucleoprotein
involved in ribosome biogenesis, again emphasizing
the ribosome as a target for transcriptional control. Four
heat shock proteins (CG1242/hsp83, CG12101/hsp60,
CG11267, and CG6603/hsc70Cb) were also identified.
For unknown reasons, silencing of these genes increased
cell size and reduced cell proliferation.
Rapamycin Increases Expression of Transcription
Factors that Control Growth
Only four genes increasing in expression 2.0-fold or more
(p < 0.01) induced cell size changes when silenced (Fig-
ure 3 and Table S1). Since rapamycin inhibits growth, we
thought it possible that silencing of these genes might
promote cell growth. Only two of the genes (CG4427
and CG6677/ash2), both encoding transcriptional regu-
latory proteins, resulted in an increased mean cell diam-
eter when silenced (Figure 3A). These genes were previ-
ously identified together in a screen for regulators of
axon guidance and synaptogenesis in Drosophila [45],
and CG4427 was also identified in a screen for genes
involved in autophagic cell death [46]. Interestingly,CG6677/ASH2 silencing increased cell size to the same
extent as the silencing of the tumor suppressors dTSC2
or dPTEN, suggesting that it too might have a tumor-
suppressor character. Although ASH2 knockdown cells
grew to a similar size as dTSC2 and dPTEN knockdown
cells, they did so by a unique mechanism because
ASH2 silencing had no effect on dS6K or dAKT phos-
phorylation, two effectors functioning downstream of
dTSC2 and dPTEN, respectively (data not shown). In
contrast, stai andmu2 appear to reduce mean cell diam-
eter when silenced. The reason for this inverse correla-
tion is unclear but could reflect a dual function for these
gene products.
Mammalian Orthologs of CG3071/SAW and CG6677/
ASH2 Are Regulated by mTOR and Control Cell Size
We wondered if our approach could identify genes with
conserved responses to TOR signaling in mammalian
cells. The human orthologs to the genes identified in
this study are listed in Table S2. We selected CG3071
based on its conservation as a representative gene that
decreased expression in response to rapamcyin and
encodes a positive growth regulator. CG3071 is 39%
identical (59% similar) to human UTP15/SAW (Src-asso-
ciated protein with WD repeats; NP_115551.2). We also
choose CG6677/ash2 as a representative gene that in-
creases expression in response to rapamycin and en-
codes a negative regulator of growth. CG6677/ASH2 is
46% identical (62% similar) to human ASH2L.
Real-time quantitative RT-PCR analysis indicates that
the expression ofSAW decreases over time in HEK-293T
cells after 3 hr of rapamycin treatment, reaching a 35%
decline in expression by 3 hr (Figure 5A). In contrast,
ASH2L expression steadily increases after rapamycin
treatment, increasing by more than 100% (Figure 5A).
We conclude that these effects are due to mTOR inhibi-
tion because identical trends in gene expression were
obtained when cells were stably knocked down for
mTOR via a previously validated lentiviral shRNA ex-
pression system [6] (Figure 5B). In these cells, SAW
levels decreased by nearly 70% and ASH2L levels again
more than doubled. mTOR mRNA levels decrease by
more than 90% in cells expressing the mTOR shRNA, in-
dicating robust silencing (Figure 5C). By means of a com-
mercially available antibody to ASH2L, we also observe
an increased level of an 80 KDa protein corresponding to
ASH2L in HEK-293T and HeLa cell lysates generated
from rapamycin-treated cells (Figure 5D). mTOR levels
are unchanged during the time course, but growth sig-
naling is inhibited as indicated by phospho-S6K1 levels
(Figure 5D). A similar increase in ASH2L protein was
observed in mTOR knockdown cells (Figure 5E). We
confirmed that this is ASH2L by reducing its expression
greater than 80% with two unique lenti-viral expressed(C) Real-time quantitative RT-PCR analysis of mRNA in HEK293T cells knocked down for mTOR, SAW, or ASH2L.
(D) ASH2L protein level increases in HEK293T and HeLa cells after rapamycin treatment. Immunoblotting was used to indicate the total amounts
of mTOR, ASH2L, S6K1, and phospho-S6K1-T389.
(E) Lenti-viral shRNAs were used to target GFP (control), mTOR, or ASH2L (two unique hairpins shown) in HEK293T cells. Total amounts of mTOR,
Raptor, and ASH2L protein after knockdown are shown by immunoblotting.
(F) Representative images of HEK293T cells expressing a GFP (control) or ASH2L shRNA.
(G) Cell-size distributions of HEK293T cells knocked down for mTOR, SAW, or ASH2L. Two unique hairpins for SAW and ASH2L were used. In
each graph, the test hairpin (red) is compared to a GFP control hairpin (black).
(H) We propose a model in which SAW (green) gene expression is positively controlled by mTOR signaling, while ASH2L transcription (red) is
suppressed by mTOR signaling.
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mycin-induced ASH2L transcriptional response trans-
lates into an increase in ASH2L protein.
We next measured the effect of silencing SAW and
ASH2L on cell size. Real-time quantitative RT-PCR anal-
ysis indicates that SAW and ASH2L mRNA levels can
be reduced by 80%–90% with at least two unique hair-
pins per gene (Figure 5C). Compared to HEK-293T cells
infected with a control shRNA to GFP, SAW knockdown
cells are reduced to roughly the same size as cells
knocked down for mTOR (Figure 5F). In contrast, cells
expressing ASH2L shRNA hairpins are significantly larger
than control cells (Figures 5F and 5G). Interestingly, the
cell size increase caused by ASH2L silencing is partially
sensitive to rapamycin, supporting the hypothesis that
other rapamycin-sensitive outputs work in combination
with ASH2L to regulate size (Table S4). Thus, as with
their Drosophila orthologs, SAW and ASH2L are tran-
scriptionally regulated by mTOR and have a functional
role in growth (Figure 5H).
Discussion
Identification of TOR-Regulated Growth Genes
We define growth as an increase in cell mass, which is
distinct from cell division, although the two processes
are coordinated [47]. How coordination is achieved is
still debated, but in many cells, cell-cycle progression
requires growth. From this model has emerged a hypoth-
esis that a ‘‘size threshold’’ exists that prevents cell-
cycle progression until a critical size is attained. When
assessing size, it is not clear what cells measure, but
the rate of protein synthesis is a good prediction. There-
fore, it is not surprising that rapamycin treatment (which
is thought to mimic nutrient deprivation) would change
the expression of genes with roles in various aspects
of setting the protein synthesis rate.
Previous studies inSaccharomyces cerevisiae investi-
gating the role of TOR in transcription determined that
yeast TOR regulates expression of metabolic pathway
genes, and in addition, ribosomal RNA and ribosomal
protein genes; transcription, translation, and replication
factors; and protein degradation genes [21, 38, 39]. Our
previous studies with mammalian cells indicated that
rapamycin affects expression of a diverse array of genes
functioning in nutrient and protein metabolism [40]. But
in these studies, a functional connection to growth was
not established. Subsequent work from the Tyers group
showed that ribosomal proteins and ribosome assembly
factors have a critical role in controlling growth [27]. Fur-
thermore, two proteins (Sfp1 and Sch9—an AGC kinase
related to AKT and S6K) that activate expression of tran-
scriptional units encoding ribosomal proteins and ribo-
some assembly factors are regulated in part by TOR
[27, 29]. Our study suggests that in higher eukaryotes,
TOR regulates expression of genes functioning in multi-
ple steps in the ribosome assembly pathway. But impor-
tantly, we found that many rapamycin-responsive genes
that are necessary for normal growth encode ribosome
biogenesis regulators, a connection not made in higher
organisms.
We further consulted previous genetic studies in Dro-
sophila to determine if any of the genes we identified by
a cell culture-based system have previously been shownto have a role in organismal growth. One positive growth
gene we identified was CG3333/Nop60B. Partial loss of
Nop60B (also named minifly) function results in severe
reduction in body size and developmental delay [48].
One positive growth and proliferation gene we identi-
fied, CG6375/pitoune/pit, is also required for cell growth
and proliferation in developing Drosophila larvae [49].
Finally, CG5786/ppan (peter pan), a gene identified in
a screen for larval growth regulators, was also found
to be required for normal growth and proliferation of
cultured cells [50]. These findings suggest that our ap-
proach led to the identification of physiologically rele-
vant genes.
While our report claims to have separated TOR-regu-
lated growth genes from genes also affecting prolifera-
tion, an important point to consider is that ‘‘knockdown’’
by RNAi, while efficient inDrosophila cultured cells, does
not substitute for a genetic ‘‘knockout.’’ RNAi can pro-
vide convincing clues to a gene’s function, but residual
expression of a target could result in an intermediate
phenotype. This could be a powerful advantage for func-
tionally annotating genes that would otherwise be es-
sential for viability. However, a cautionary interpretation
should be applied when using RNAi as a tool to distin-
guish pure growth genes (i.e., genes that affect only
cell growth) from genes that control growth and prolifer-
ation. It is possible that for some genes, knockdown was
sufficient to inhibit growth, but perhaps a more robust
knockdown would inhibit cell-cycle progression. Fur-
thermore, our study primarily looks at individual mean
cell size as the readout for growth, and growth is defined
as an increase in mass. For some genes, such as
CG11267 and Hsc70Cb, knockdown increased cell size
but greatly reduced cell number, thereby reducing total
cell mass of the population. Along the same lines,
a gene that increases cell number but not cell size would
increase the total mass of a cell population. Thus, con-
sideration of the global cell population number in addi-
tion to mean cell size after gene silencing can provide
more information about a gene’s function in growth.
However, making these predictions here is again chal-
lenged by the incomplete nature of knockdowns versus
knockouts. Future studies that use genetic knockout
models should address these concerns on a gene-by-
gene basis.
Nutrient Control of Gene Expression in Growth
and Disease
Nutrient control of gene expression and growth has
emerged as a principal concern in the modern era as
diet-induced diseases become more prevalent. It is be-
lieved that mTOR is at the core of an ancient growth
pathway that senses nutrient levels, particularly amino
acids, and that rapamycin treatment mimics a ‘‘starva-
tion-like’’ state. A previous study employing Affymetrix
microarrays identified a set of genes in developing Dro-
sophila larvae that respond to starvation [51]. 42% of the
19 genes identified by Zinke et al. as responding nega-
tively to amino acid starvation were also rapamycin-
sensitive genes: a remarkable similarity considering
the difference in source material and statistical analysis.
If we consider all the genes whose expression decreased
significantly (p < 0.01) after rapamycin treatment, we find
that 68% of the genes in the list of Zinke et al. are also in
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significantly increasing expression upon starvation (14
total) passed our cutoffs to be functionally analyzed, 4
of them (28%) did significantly increase expression in
response to rapamycin. One of those genes encodes
Thor, the Drosophila 4E-BP ortholog. Both the Zinke
et al. study and our study used early versions of theDro-
sophila Affymetrix chip (‘‘DrosGenome1’’), and therefore
there might be additional nutrient- and rapamycin-sensi-
tive genes to be discovered.
An appreciation for the role of mTOR in tumorigenesis
has emerged from clinical trials indicating that rapamy-
cin might be an effective treatment for some cancers (re-
viewed in [1]). A general idea is that upregulated mTOR
signaling provides tumors with a growth advantage by
promoting translation initiation through S6K1 and 4E-
BP1. However, it cannot be ruled out that other mTOR-
regulated process such as transcription and autophagy
are relevant in cancer and other diseases. These pro-
cesses are conserved in yeast and represent ancient
functions of TOR. Perhaps mTOR-regulated genes could
be important targets for antigrowth drugs. The fact that
many of the growth genes we identified block the TSC2
RNAi-induced cell size increase when cosilenced sup-
ports such a notion.
Genes with specific links to human disease were also
identified in this report. Nop60B (CG3333) is the Dro-
sophila ortholog of human DKC1 (dyskerin), the gene
mutated in dyskeratosis congenita (DC) [48]. DC is a rare
X-linked recessive disease initially characterized by nail
dystrophy, abnormal skin pigmentation, mucosal leuco-
plakia, and premature aging, with patients often suc-
cumbing to bone marrow failure before the age of 30
[52]. DKC1 encodes a pseudouridine synthase, which
associates with box H/ACA small nuclear RNAs and
posttranscriptionally modifies rRNA by converting uridine
to pseudouridine. In yeast, the DKC1 ortholog (Cbf5p) as-
sociates with Nhp2p[52], theDrosophilaorthologof which
(CG5258) was also identified in our screen. Patients with
DC are predisposed to tumor formation, and this is mim-
icked in a mouse model in which half of Dkc1 mutant an-
imals develop tumors [53]. It is perhaps paradoxical that
mutations apparently compromising ribosome function
promote tumorigenesis. However, a screen for cancer
genes in zebrafish identified several ribosomal protein
genes as haploinsufficient tumor suppressors [54], sug-
gesting that ribosome dysfunction may have an impor-
tant but undefined role in promoting tumor formation.
The human ash2/CG667 gene product (ASH2L) was
discovered in a histone methyltransferase (HMT) com-
plex with the tumor suppressor menin [55]. Menin is
encoded by the MEN1 gene, which is mutated in familial
multiple endocrine neoplasia type 1 [56–58]. Several
MEN1 point mutations found in tumors are associated
with reduced HMTase activity of the complex [55]. An-
other report found ASH2L associated with a HMT com-
plex containing the Leukemia protooncoprotein MLL,
the human ortholog of Drosophila trithorax, in addition
to menin [59]. Interestingly, Drosophila ash2 mutant
cells in genetic mosaics exhibit defective cell differenti-
ation and increased cell size, consistent with our conclu-
sions [60]. In another report, Drosophila ASH2 localized
to the nucleolus, suggesting that ASH2 might have a role
in rDNA transcription [61]. The yeast ortholog of ASH2is part of the SET1 complex, which in one study was re-
ported to repress rDNA transcription by promoting H3
Lys4 methylation of rDNA [62, 63]. Elucidating the func-
tion of ASH2 in cell growth and differentiation might un-
cover clues to understanding the tumor-suppressor
functions of these HMT complexes.
Conclusions
In this report we combined gene expression profiling
with functional analysis by RNAi to identify Drosophila
genes that are responsive to acute rapamycin treatment
and that regulate cell growth and proliferation. This ap-
proach allowed us to functionally annotate 54Drosophila
genes. Most of the genes have orthologs in species rang-
ing from yeast to mammals, and some are implicated
in human disease. With genome-scale RNAi libraries be-
coming available in many organisms, we conclude that
similar combinatorial approaches might be useful in de-
termining subsets of ‘‘enriched’’ genes that could be
functionally analyzed by targeted RNAi. This study found
a rapamycin-sensitive growth-gene set in Drosophila
cultured cells. In addition to emphasizing the role of
TOR-dependent transcription in growth, we identified
human genes with similar transcriptional and functional
roles. We further conclude that similar approaches in
model systems with comparatively simpler genomes
can be an effective way to predict human gene function.
Experimental Procedures
Sample Preparation for Affymetrix Drosophila GeneChip Array
analysis
DrosophilaS2 cells were diluted into 6-well culture dishes at 2.53106
cells/ml in a total volume of 3 mL 24 hr prior to drug addition. The fol-
lowing day, rapamycin was added into the culture medium to a final
concentration of 20 nM. Control wells were treated with ethanol, the
vehicle solvent for rapamycin. Cells were allowed to incubate for 30,
60, or 120 min before total RNA was isolated by an RNeasy kit (Qia-
gen). Total RNA isolation was performed in duplicate for each time
point except T0, which was done in quadruplicate. Early time points
were chosen to avoid gene expression changes that might be sec-
ondary effects of arresting division. Total RNA was processed for
GeneChip analysis by the Whitehead Institute center for microarray
technology with the Enzo BioArray HighYield RNA transcript labeling
kit. The final target mix was hybridized toDrosophilaAffymetrix Gen-
eChips (Affymetrix DrosGenome1) and scanned with a GeneChip
Scanner 3000.
GeneChip Data Analysis
Expression values for each probe set were calculated with the Affy-
metrix MAS 5.0 algorithm and transformed for each chip to produce
a global median of 100. Replicates were combined to calculate fold
changes, and differential expression was determined with Welch’s
test (raw p < 0.01) (by means of the four 0 time point chips as con-
trols), together with fold change (>2). Few genes showed significant
differential expression on the ethanol control chips for each time
point; those that did were considered ethanol-specific genes and re-
moved from the final probe-set list. All remaining probe sets showing
differential expression for at least one time point were compiled, log
transformed, grouped according to up/down profiles across three
time points and ordered by decreasing magnitude of change. K-
means clustering was performed by means of the Pearson correla-
tion (uncenterred) metric with Cluster 3.0. Heatmaps were produced
with Java TreeView. A table of genes and their expression values,
fold change, and significance values after rapamycin treatment or
knockdown can be found on our website at http://web.wi.mit.edu/
sabatini/pub/protocols.html. For Gene Ontology analysis, we used
Flybase annotations (http://flybase.bio.indiana.edu/). Overrepre-
sented GO terms were identified by comparison with LocusLink
Current Biology
968D. melanogaster genes by the hypergeometric distribution. Only 29%
of the genes represented on these GeneChips had GO annotations.
RNAi Methods
A detailed description of ourDrosophilaRNAi methods can be found
at http://jura.wi.mit.edu/sabatini_public/fly_array/ and is discussed
in the Supplemental Experimental Procedures.
Mammalian RNAi methods are described in [8]. The sequences of
the SAW and ASH2L oligonucleotides are listed in the Supplemental
Experimental Procedures.
Cell Size Analysis
Cell size and number was measured with a coulter counter (Beckman
Coulter). For cell size analysis after knockdown, S2 cells were incu-
bated 4 days after dsRNA addition and then resuspended by gently
pipetting up and down 10–15 times to assure even distribution of
cells. A 100 ml volume of cells was subsequently added to 9.5 ml of
Isoton II Diluent and mixed by inverting two times, and cell size and
number were measured. Silencing events that affected cell size in
our functional analysis of rapamycin-sensitive genes were repeated
with newly synthesized dsRNA for confirmation. Similar methods
were employed for measuring mammalian cell size except that cells
were first trypsinized, then resuspended in cell culture medium. Cell-
size distribution curves were generated by plotting cell size versus
the number of cells in each bin of the indicated size. Testing for
significant cell size change was performed with Welch’s test, with
p value adjustment by the FDR procedure.
Immunoblotting
A detailed description of the cell lysis methods can be found in the
Supplemental Experimental Procedures. Antibodies were obtained
from the following sources: phospho-T389 S6K1 and Raptor anti-
bodies from Cell Signaling. Total Drosophila S6K antibody from
Mary Stewart, North Dakota State University; mTOR and mammalian
S6K1 antibody from Santa Cruz; and ASH2L antibody from Bethyl
Laboratories.
Real-Time Quantitative RT-PCR
A master mix containing TaqMan Universal PCR Master MIX (Abi
4304437), primer/probe set, and ddH20 was prepared and distrib-
uted in a 384-well qPCR plate (Abi 4309849). GAPDH was used as
the control. cDNA, prepared with a SuperScript first strand synthesis
system (Invitrogen) from total cellular RNA isolated with an RNeasy
kit (Qiagen), was added to the reaction mix. The reaction was run on
an ABI Prism 7900HT real-time PCR machine. For each experiment,
reactions were done in triplicate (n = 3), resulting in a standard devi-
ation and error of less than 0.5 in all cases.
Supplemental Data
Supplemental Data include three figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article
online at http://www.current-biology.com/cgi/content/full/16/10/
958/DC1/.
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